Q4 EPS Estimate for ARS Pharmaceuticals Boosted by Analyst

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) - Research analysts at William Blair boosted their Q4 2025 earnings per share (EPS) estimates for shares of ARS Pharmaceuticals in a note issued to investors on Wednesday, November 13th. William Blair analyst L. Hanbury-Brown now anticipates that the company will post earnings of $0.05 per share for the quarter, up from their prior forecast of $0.02. William Blair currently has a "Strong-Buy" rating on the stock. The consensus estimate for ARS Pharmaceuticals' current full-year earnings is ($0.64) per share.

Several other research analysts also recently weighed in on SPRY. Leerink Partners increased their price target on shares of ARS Pharmaceuticals from $21.00 to $25.00 and gave the stock an "outperform" rating in a research report on Friday, September 20th. Cantor Fitzgerald reiterated an "overweight" rating and set a $30.00 target price on shares of ARS Pharmaceuticals in a research report on Tuesday, October 8th. Finally, Raymond James upgraded ARS Pharmaceuticals from an "outperform" rating to a "strong-buy" rating and upped their price target for the stock from $18.00 to $22.00 in a research report on Tuesday, August 13th. Four analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Buy" and an average target price of $24.00.

ARS Pharmaceuticals Price Performance

Shares of SPRY traded down $0.10 on Friday, reaching $14.01. The company's stock had a trading volume of 1,533,642 shares, compared to its average volume of 811,040. The stock's 50 day simple moving average is $14.58 and its two-hundred day simple moving average is $11.67. The stock has a market capitalization of $1.36 billion, a P/E ratio of -27.67 and a beta of 0.90. ARS Pharmaceuticals has a 12-month low of $4.28 and a 12-month high of $18.51.

Insiders Place Their Bets

In other news, major shareholder James E. Flynn sold 528,456 shares of ARS Pharmaceuticals stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $18.04, for a total value of $9,533,346.24. Following the sale, the insider now directly owns 5,274,735 shares of the company's stock, valued at approximately $95,156,219.40. The trade was a 9.11 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, COO Brian Dorsey sold 50,000 shares of the company's stock in a transaction that occurred on Tuesday, August 20th. The stock was sold at an average price of $15.00, for a total value of $750,000.00. Following the sale, the chief operating officer now directly owns 6,024 shares in the company, valued at $90,360. This trade represents a 89.25 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 1,584,351 shares of company stock worth $24,152,378. Corporate insiders own 40.10% of the company's stock.

Institutional Trading of ARS Pharmaceuticals

Large investors have recently made changes to their positions in the business. nVerses Capital LLC bought a new position in ARS Pharmaceuticals during the 3rd quarter valued at about $30,000. Russell Investments Group Ltd. purchased a new stake in ARS Pharmaceuticals in the first quarter worth about $60,000. Zurcher Kantonalbank Zurich Cantonalbank increased its position in ARS Pharmaceuticals by 151.7% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,419 shares of the company's stock valued at $63,000 after purchasing an additional 4,472 shares during the period. Principal Financial Group Inc. purchased a new stake in shares of ARS Pharmaceuticals in the 2nd quarter worth approximately $87,000. Finally, Paloma Partners Management Co bought a new position in shares of ARS Pharmaceuticals during the first quarter valued at approximately $103,000. 68.16% of the stock is currently owned by institutional investors.

About ARS Pharmaceuticals

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.